{"ticker": {"uuid": "c014b0bf-2487-493d-b5b7-7d4c5141e2d0", "symbol": "ADCT", "name": "ADC Therapeutics SA", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates", "summary": "This press release details ADC Therapeutics' financial results for the first quarter of 2026 and provides operational updates. It likely includes key financial figures such as revenue, net income/loss, and expenses, along with information on clinical trial progress, regulatory su", "url": "https://www.moomoo.com/hant/news/post/69338487/press-release-adc-therapeutics-reports-first-quarter-2026-financial-results?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-11T12:10:08", "published_display": "11 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award", "summary": "ADC Therapeutics (ADCT) has granted its CFO, Jose Carmona, 203,700 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs will vest on June 30, 2027, or earlier under specific termination events, provided continued employment. This award increas", "url": "https://www.stocktitan.net/sec-filings/ADCT/form-4-adc-therapeutics-sa-insider-trading-activity-dfd099c7c1ac.html", "source_name": "Stock Titan", "published_at": "2026-07-03T09:40:50", "published_display": "03 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing", "summary": "ADC Therapeutics SA's CEO, Ameet Mallik, was granted 675,000 restricted stock units (RSUs) on June 30, 2026, as reported in a Form 4 SEC filing. These RSUs, which have a price of $0.00 per unit, will vest on the earlier of June 30, 2027, or upon certain qualifying terminations of", "url": "https://www.stocktitan.net/sec-filings/ADCT/form-4-adc-therapeutics-sa-insider-trading-activity-45f82ed01322.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:10:29", "published_display": "02 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares", "summary": "ADC Therapeutics' Chief Medical Officer, Zaki Mohamed, was granted 213,900 Restricted Stock Units (RSUs) on June 30, 2026, as an equity award. This compensation-related grant increases his direct holdings to 896,317 common shares. The RSUs will vest on the earlier of June 30, 202", "url": "https://www.stocktitan.net/sec-filings/ADCT/form-4-adc-therapeutics-sa-insider-trading-activity-674e12b45bb0.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:17", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer", "summary": "ADC Therapeutics (ADCT) announced that its Chief Legal Officer, Peter J. Graham, was granted 221,100 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs, which represent common shares, will vest on the earlier of June 30, 2027, or specific te", "url": "https://www.stocktitan.net/sec-filings/ADCT/form-4-adc-therapeutics-sa-insider-trading-activity-7ef6a267d0f6.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:17", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive retention awards approved at ADC Therapeutics (NYSE: ADCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQYjdNQldfbmZ6S3dJc0dWY25tdUlPbXkzRkc5TnRZeVVOcjBoTF80alBoNnNZSWlWNXNmbEp4MF9YOWk3TXJTQnpESmpteW14ODNCdzRuUDkySllVSmF4dFlBNXFtWjlxQzVFQmdvNVJtaHIwRXpMOGI4aGtIbDVsSGlVcmhEeHAtcjFaWTE5b2hCS0pheVU4X3Z3WnBhOE5jT1JlM0ZEZGJOZU5C?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Announces New Employee Inducement Grant", "summary": "ADC Therapeutics SA (NYSE: ADCT) has announced an inducement grant of options to purchase 17,000 common shares for a new employee. This grant, approved by the Compensation Committee, aims to retain top talent and relies on the employment inducement exemption under the NYSE's List", "url": "https://www.prnewswire.com/news-releases/adc-therapeutics-announces-new-employee-inducement-grant-302816307.html", "source_name": "PR Newswire", "published_at": "2026-07-01T20:05:19", "published_display": "01 Jul 2026 20:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics gives new hire 17,000-share inducement award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUUNhcFJ1WTZLdTNIUFVjWkFJeGVBYTJVajhvdjNNSzNBZkcwU3dqNUM1SnlCQ2xvZk5DTS1MUjRxVDQ0NHFiaG91TEFZOXNYZFNUeDI0T0JibFp3UHYzWE5hRUtvUl90U0JidUZLZ09JWllmWkhVUkxqSTFNWmdMQkZwWjlkMnV5ZndvOXhnR2N4Q2NwZDVKR3gxdmRGUEJTZlJXdDFtaTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL", "summary": "ADC Therapeutics has completed enrollment of 100 patients in its Phase 1b LOTIS-7 trial, evaluating a combination of ZYNLONTA and glofitamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial has shown an 89.8% overall response rate and a 77.6% complete resp", "url": "https://www.biopharminternational.com/view/adc-therapeutics-completes-enrollment-in-lotis-7-advancing-zynlonta-glofitamab-combination-in-dlbcl", "source_name": "BioPharm International", "published_at": "2026-06-30T18:10:27", "published_display": "30 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/adc-therapeutics-completes-enrollment-lotis-131624284.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:16:24+00:00", "published_display": "30 Jun 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics completes LOTIS-7 trial enrollment", "summary": "ADC Therapeutics has completed enrollment for its Phase 1b LOTIS-7 clinical trial, which investigates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 100 patients and aims to assess the saf", "url": "https://grafa.com/en/news/united-states/adc-therapeutics-lotis7-zynlonta-glofitamab", "source_name": "grafa.com", "published_at": "2026-06-30T14:10:27", "published_display": "30 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics completes enrollment in LOTIS-7 trial", "summary": "ADC Therapeutics has completed enrollment in its LOTIS-7 Phase 1b clinical trial, evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma. The company reported promising initial response rates from earlier data and anticipates s", "url": "https://www.investing.com/news/company-news/adc-therapeutics-completes-enrollment-in-lotis7-trial-93CH-4767528", "source_name": "Investing.com", "published_at": "2026-06-30T12:10:27", "published_display": "30 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial", "summary": "ADC Therapeutics announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA\u00ae in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients at the selected 150 \u00b5g/kg dose ", "url": "https://www.prnewswire.com/news-releases/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-302813948.html", "source_name": "PR Newswire", "published_at": "2026-06-30T11:10:27", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in ADC Therapeutics Ltd Stocks", "summary": "This article lists several ETFs that hold ADC Therapeutics Ltd (ADCT) stocks, providing financial details for each fund. The ETFs include those focused on small-cap growth, biotechnology, micro-cap companies, and healthcare innovation, with varying management styles and expense r", "url": "https://www.tradingview.com/symbols/NYSE-ADCT/etfs/", "source_name": "TradingView", "published_at": "2026-06-29T16:41:09", "published_display": "29 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index", "summary": "ADC Therapeutics SA (ADCT) has been added to the Russell Microcap Value Benchmark Index. This news follows a previous announcement on the same day that the company was added to the Russell 2000 Value Benchmark. The company, a clinical-stage oncology drug developer, recently repor", "url": "https://www.marketscreener.com/news/adc-therapeutics-sa-nyse-adct-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd988f724", "source_name": "marketscreener.com", "published_at": "2026-06-29T13:41:09", "published_display": "29 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma", "summary": "ADC Therapeutics (NYSE: ADCT) has completed enrollment for its LOTIS-7 Phase 1b trial, which evaluates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients across 30 sites, buil", "url": "https://www.stocktitan.net/news/ADCT/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-amg8g6sm2cgk.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:41:35", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ADC Therapeutics SA \u2013 NYSE:ADCT", "summary": "This article provides financial information for ADC Therapeutics SA (NYSE: ADCT), specifically focusing on its enterprise value to revenue forward metric. The data is presented within the context of TradingView's platform, indicating that the metrics are available for investor an", "url": "https://www.tradingview.com/symbols/NYSE-ADCT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:40", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPN01uYUJZMzhXT0Nlckw1X01CdjVTcmVhaC12anpvdHhQWDExbTA0cm1zaDJkZXA3WHVTNEk1ZHpfekR1dW56c2w0d0ZicFFJMEZOcDU3UlF1ckwyVy10bmhXR3FsTFhtSjRqVjB4SXBydnU2bmVIM0RKZmhMcnU2cTdjd3R0SFpuNVBGcDR4UlZKQVlHODdzZQ?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ADC Therapeutics SA \u2013 NYSE:ADCT", "summary": "This article provides a brief financial data point for ADC Therapeutics SA (NYSE:ADCT), specifically regarding its price-to-earnings forward ratio. The content is sparse, indicating \"Period Value Change Change %\" but without specific numerical data. It appears to be a stub or a s", "url": "https://www.tradingview.com/symbols/NYSE-ADCT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:11:20", "published_display": "27 Jun 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Ltd Actuals & Estimates (NYSE:ADCT)", "summary": "This article provides an overview of ADC Therapeutics SA (NYSE:ADCT) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price targets, upcoming earnings dates, and past financial results lik", "url": "https://www.tradingview.com/symbols/NYSE-ADCT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:14", "published_display": "26 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics launches restructuring around ZYNLONTA", "summary": "ADC Therapeutics (NYSE:ADCT) is undergoing a strategic reorganization focusing on its ZYNLONTA franchise and related clinical trials. The restructuring involves an estimated 17% workforce reduction, expected to save $10 million annually, and aims to extend the company's cash runw", "url": "https://grafa.com/en/news/united-states/adc-therapeutics-restructuring-zylnonta-lotis", "source_name": "grafa.com", "published_at": "2026-06-24T16:11:03", "published_display": "24 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics plans 17% workforce cut to save ~$10M annually, $3M one-time charges", "summary": "ADC Therapeutics announced a global workforce reduction of approximately 17% to achieve about $10 million in annualized cost savings. This reduction is primarily due to the completion of the LOTIS-5 and LOTIS-7 programs and aims to enhance financial flexibility. The company expec", "url": "https://www.tradingview.com/news/tradingview:7482aefdde3ff:0-adc-therapeutics-plans-17-workforce-cut-to-save-10m-annually-3m-one-time-charges/", "source_name": "TradingView", "published_at": "2026-06-24T13:11:03", "published_display": "24 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (NYSE: ADCT) trims workforce 17% to back ZYNLONTA trials and extend cash runway", "summary": "ADC Therapeutics announced a strategic reorganization involving a 17% global workforce reduction to focus on its ZYNLONTA franchise. This move is expected to generate $10 million in annualized cost savings against $3 million in one-time charges, extending the company\u2019s cash runwa", "url": "https://www.stocktitan.net/sec-filings/ADCT/8-k-adc-therapeutics-sa-reports-material-event-0799bfe43e91.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:11:03", "published_display": "24 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Cuts 17% of Workforce, Targets $10 Million in Annual Savings", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/adc-therapeutics-cuts-17-workforce-114530049.html", "source_name": "MT Newswires", "published_at": "2026-06-24T11:45:30+00:00", "published_display": "24 Jun 2026 11:45", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA\u00ae Growth Opportunities and Regulatory Priorities", "summary": "ADC Therapeutics (NYSE: ADCT) has announced a strategic reorganization, including a 17% global workforce reduction, to enhance financial flexibility and focus on ZYNLONTA\u00ae growth. The company expects to save approximately $10 million annually, driven by the anticipated completion", "url": "https://www.prnewswire.com/news-releases/adc-therapeutics-announces-strategic-reorganization-to-support-zynlonta-growth-opportunities-and-regulatory-priorities-302808358.html", "source_name": "PR Newswire", "published_at": "2026-06-24T11:11:03", "published_display": "24 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics To Cut About 17% Of Its Staff \u2013 A Look At Some Key Details", "summary": "ADC Therapeutics (ADCT) announced a 17% workforce reduction to focus on its ZYNLONTA franchise and upcoming regulatory milestones, including a pre-supplemental Biologics License Application with the FDA in August 2026. This move is expected to generate $10 million in annualized c", "url": "https://stocktwits.com/news-articles/markets/equity/adc-therapeutics-in-focus-layoffs-reorganization-zynlonta-franchise/cZKya9bR7fg", "source_name": "Stocktwits", "published_at": "2026-06-24T09:13:00", "published_display": "24 Jun 2026 09:13", "sentiment": "negative", "sentiment_pct": 37, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics trims 17% of staff to fund ZYNLONTA push", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbXlGMkNsSkc2bk1HR3ZpU2laMHZVMEkxMVZqb1ViVEkyRTA0cEVIYWN1LUJXVUFNVUZSQmlZNmpJODM3SXdMcmpkSm9OczhaRFNCeU5vVnNqNGNGTXdYSkFibnVRRG9qQkJsemI1b3FqRGpYZkdGck1ZMHlYdW9hR3hVcE9xZnZaZjNBTExzOC1abnVXRUFjSzZVSU5mdWFMSGc0b2RSbmlpM1RKOEF4NmlILVZXN2Ez?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) following a significant drop in stock price. This investigation comes after ADC announced topline data from its Phase 3 LOTIS-5 trial, where their treatment,", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-adc-therapeu-1174146", "source_name": "ACCESS Newswire", "published_at": "2026-06-23T05:10:42", "published_display": "23 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (ADCT) following a significant drop in its stock price. This investigation comes after the announcement of top-line data from ADC's Phase 3 LOTIS-5 trial, which, despite extending pro", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1174144", "source_name": "ACCESS Newswire", "published_at": "2026-06-19T11:00:00", "published_display": "19 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ADC Therapeutics\u2019 loncastuximab tesirine is still on oncologists\u2019 radar", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOajVKZ2dGSGd1ajRaclNaNVZwQi02X0ZCV2s4QVRSSk9KS1lUbWZCYVk2UmpGdXJBU2x4VklLTXU2bTdzaF9pb2NkS3Y4YTcyRjM0RW5FTy0tNnk4LXU5T09ETWJub0JLWFpvZUh2eTkzQm01dHVuTEc3cnI0ZWpNWHowX0owVUUtRWZQdHRsTEpsYmc4TVVIdnJaLW1uLW5wandZUTlobzJqQ2RFaXFhMzlrcjMtVkpEOTEwTHBNcGgwdTRW?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-19T02:17:12+00:00", "published_display": "19 Jun 2026 02:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT", "summary": "Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (ADCT) on behalf of investors. This investigation follows a significant drop in ADC's stock price after the company released topline data from its Phase 3 LOTIS-5 trial for ZYNLONTA\u00ae, whi", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adc-therapeutics-sa---adct-302802881.html", "source_name": "PR Newswire", "published_at": "2026-06-18T13:59:46", "published_display": "18 Jun 2026 13:59", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics SA (ADCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for ADC Therapeutics SA (ADCT), detailing its business segments. It shows that Product sales account for 90.41% of revenue, followed by License revenue at 6.15%, and Royalties at 3.45%. The article also notes that relevant regional data f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adct/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:46", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (NYSE:ADCT) following a significant stock price drop. This drop occurred after the company announced Phase 3 trial data for ZYNLONTA\u00ae, which, despite extending progression-free surviv", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/adc-therapeutics-sa-adct-investigation-bronstein-gewirtz-and-gro-1174142", "source_name": "ACCESS Newswire", "published_at": "2026-06-17T20:39:51", "published_display": "17 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) securities. This investigation follows the announcement of topline data from ADC's Phase 3 LOTIS-5 trial, where ZYNLONTA\u00ae extended progression-free survival ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-adc-therapeutics-s-1174140", "source_name": "ACCESS Newswire", "published_at": "2026-06-15T16:40:31", "published_display": "15 Jun 2026 16:40", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Shares Fall After HC Wainwright Downgrade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adc-therapeutics-shares-fall-hc-185243246.html", "source_name": "MT Newswires", "published_at": "2026-06-08T18:52:43+00:00", "published_display": "08 Jun 2026 18:52", "sentiment": "negative", "sentiment_pct": 22, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA Data - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQN0xDZGsxR1BWVkVQQ0xMUGF4OEJpQmRFcXB0SHNBN2UzaEpzTUhaN0hlRFh1WW5tZ01kQ2ctQVFTRGdqVjk3Z05BbHhCb1g1WlQzRWUwaHJuYVdmZGlfdVdhcXc3cUhkbE44R29EMmNweWxUdnAySUg3SWtkLXF4WVZnTGpFSjI4YW9Sa244eE9WUUt2TTJWZVg4eWlDS1k?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQS21uUlJGeEp6UmUzSlYwQ2pjYUswRk1XY2ljYU1jeUFTRzg5RDhzUzVUYlBQeHhIZ0ZIc3NwMFdnQ2RrcDA0blBxQUJYVXJUT0xOU2FYWkpqczhjd2FVZTJ5RmVPOUFQSi1fYzFMdGN4M1RGak01bjNGQ1BKNERCbXpXNHQ4ZHFEQ2xyOVktREU5U0pwWDBmb25NVERzUUZEN1JnUDJJTFVLak9iV1FtV1Z1VTYtdzE2LS03Tjdrd0hKRlFvSzlyc21vbGRDZXRUMDVtMU5tS0cwcjJFbXJSWGU1aEkzdw?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics plunges after patient deaths in blood cancer drug trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPQnNxUXE1czUwRnI5M2pHdklYQXZBQk5kUlJWZ2t5TEgtQ3A0Z2ZoRHFNejhNWi1MOElPVHdQOXcxYzl1akY3RS1DNE5HYTN4Q2oxMXB5SkFLWDFNQUltS3M2NGZKU0thLU1EMS01UnA0TTZWSl9QcU1zMkxPQXJKSG1lOTBFUEFyNVVCZEZqWWhYR2ZlalJtY2g5NEVNemxXNlBpdE1xeXREdjFUWTZtalRnSkUtNjMwNHJDRzZ6ZFY0TzlVR1A0V2RzUU9jaERLa2hEOUVpdzY?oc=5", "source_name": "Reuters", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LOTIS-5 trial: ADC Therapeutics (NYSE: ADCT) shows PFS gain but higher toxicity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQNGNraGE5OE1iNVJkV0pyRG1qYU9CUTBjS2daN1BXS2xsel9mSGFoWURoZzJqNVVraXF3a2VaZFdGeS1nSmNla2Q2ZU4yY1RGY0JsODAzd2xnOUVYSjBxdVFaUkFNdm1JQl9WREk5NWR3RUFBNHJLSmpKYkFsRklJbkd0aGp6YXhwNmRsbEFfczVBMHJfYWhicVJiSkNUaFdlNUpfNXEzVDRkbV9q?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) investors approve pay limits, equity plan and capital increases", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPajJhZW5TWWx5Tjd4azVEQ2RwSkx2N3Q3RDVQZkQ2eW1pcks0UmdxZGN6U09zNndDWjFxdHZhVXNtc3V0WWNKTFdCRHRDc2ZvZ0RHQjVqeExJaUktVjdFTWhyYnc0emV3d2g5aERhOUNSVkdSMWF5YkFMblZJOXJCTGdhOE5sNWZycVdCd2xHMlJVTVhVVl9LTGVnTkRUTUNRa20xd2VXd0hwbUY2?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNR045UFZhak5fQzVzQ3B2cnozeWFKN0luQnZCTC15dVlOcllyV1otSENPckVNd2ZlVnBac01JZUdwT0hfVVd2TERHNFk5OWEzbXNzNVZhZlE2TllMNk83ajRSWkh6d2pzS2pycVROVVd1ZjFfbllzVFZYeVBtczhCWll1Vi1wVGpfX0hwZDczYU9pc2ZlR25uWHEwaElaUVk1ZTRQamxpcGFpT0lrSS1vWXdIZmNjdXRkeXlkZ2dTODltMlBtem9DVktzbU5mU1lmeGVTR1dyV2MzVEJFejBHcXh5MHY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNUkZjZVdlVEc4bUN1SFNrVGtIT0NWT1lqcDFlY0xnR2xPcnViUVBqMEJyYzJYUmJJRWp2SGV3SHNQemlOSkQ0VUI4dGFYd2VXQWdtR3R3VG9SNVhDbmp1VXRrb0kySUROMHk0TTZXY25JUDNJY2l3Q2h3XzFLakJvT1FuT00wSFdL0gGIAUFVX3lxTE1SRmNlV2VURzhtQ3VIU2tUa0hPQ1ZPWWpwMWVjTGdHbE9ydWJRUGowQnJjMlhSYklFanZIZXdIc1B6aU5KRDRVQjh0YVh3ZVdBZ21HdHdUb1I1WENuanVVdGtvSTJJRE4weTRNNldjbklQM0ljaXdDaHdfMUtqQm9PUW5PTTBIV0s?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new hires at ADC Therapeutics receive 49,400 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQQ3Y5cHNDYkRIYlRhM3RWQWR2cEZCV0p6WnAxazRQUExXcklOUmZfWnpRVFBzTlpFeTdEdGZGUk9zbmJvOW9ibmNQMlgzVVdqSG50TGFfalVvLTQwYWhTRzNCTkN0Q19kaHlmMDZnWjAtOEFQMzZvc1pIM093RnBSbHpCUzRoT3BqNXpkS2xKQ1VtT3JhTzlOaGZBcVUzUmJxQnlSVHVkVkxPSmFYQTAyUU95bHBBR3NxWmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcV9pVnVxQU53WGxVWXFMdndMczg2ZWgxSGgxcTNGcFM2c1dpUk5HMm0zMkMtU185dzBtWWRmUWoyOGRVUDF6SnV1WHJTOGhycUlMMnZDR2lhSXdpNm9EdEl3azg5SmhldXJHZEFqNGhodjAzLWp5Z3otQ0NKa2V0cjhZd05LdzROZXFzVGpXclQ1ZVhzWVBJNi1lcWtUR3gtS2gzWnZZLS0xdw?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbnFqeFdua2MzSW91bmQ5RHFCSDMyeDUxbllONlNCY2hLa040VVBzeER3WkRLRUtsNncwc081YVJPQ19VQUFCak0wVF9pWm41WmxaZFQ4STQ4a21xWXYzQjA0SzlmYS1xc3ZscTdCMjVQSVROSzRZaWtETm5NX1ZjeHowdGVsQkE1eG1YaWpiYU9WWFFpV2NPYlJRQ1NvZkhsY3BrQmR6ZzE4WGxEcG5DLXpsR3ZCVmhNTlRzUTF6OTJDXzFJY0p1YUxqVTVQQjRoUUtiU1Q1ZjlsZy1sckRPcG5tR0FhMnE3R3VZT3NoUEdJV2JFVDVZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQTUtxNENZNmN0eVl3QTJXZ19tWi15dC1xWVlHQmVBUVZuUEhnU21GalpoTG9vTW1HcjRBMGwtR2VEb3FXLU9tZlFLNWt4YThrcS04RzNoWjFYV000QmFDb0V0MzVGNVczT0J0UzVzbzh6VHJpX0RZdTlxRWx0ZEZHV05BRXI?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNUzdBRGhxRlYwRE5fczZCZDlsREJsQk1OYlpLY2VfMHBZdkNBSktqX3JBSzFEeTVTOEdaVW9kdzY5MHhkYTZVOGY3VkxvVWRfVVhKYnZOMHZoTzVvaHVwLUNha1JWWm5vMHhwSHhCZ2RVLXM2WXpsRkhfbEVELXlLWnpuZ2hKU1lKZnFrd1VMb01BSnJCX1JDN2wwY1Z3aVRJTGhDVG5xeS1PMFU4NkxIV2hFTndaeXRsQ2JNS252VFlPWmRpRWhYb0VHeVV0TjJvaUpma1BwRm1xSElxaDR2cHBMUFhCamVJ?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-12T07:00:00+00:00", "published_display": "12 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates", "summary": "This press release details ADC Therapeutics' financial results for the first quarter of 2026 and provides operational updates. It likely includes key financial figures such as revenue, net income/loss, and expenses, along with information on clinical trial progress, regulatory su", "url": "https://www.moomoo.com/hant/news/post/69338487/press-release-adc-therapeutics-reports-first-quarter-2026-financial-results?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-11T12:10:08", "published_display": "11 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award", "summary": "ADC Therapeutics (ADCT) has granted its CFO, Jose Carmona, 203,700 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs will vest on June 30, 2027, or earlier under specific termination events, provided continued employment. This award increas", "url": "https://www.stocktitan.net/sec-filings/ADCT/form-4-adc-therapeutics-sa-insider-trading-activity-dfd099c7c1ac.html", "source_name": "Stock Titan", "published_at": "2026-07-03T09:40:50", "published_display": "03 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing", "summary": "ADC Therapeutics SA's CEO, Ameet Mallik, was granted 675,000 restricted stock units (RSUs) on June 30, 2026, as reported in a Form 4 SEC filing. These RSUs, which have a price of $0.00 per unit, will vest on the earlier of June 30, 2027, or upon certain qualifying terminations of", "url": "https://www.stocktitan.net/sec-filings/ADCT/form-4-adc-therapeutics-sa-insider-trading-activity-45f82ed01322.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:10:29", "published_display": "02 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares", "summary": "ADC Therapeutics' Chief Medical Officer, Zaki Mohamed, was granted 213,900 Restricted Stock Units (RSUs) on June 30, 2026, as an equity award. This compensation-related grant increases his direct holdings to 896,317 common shares. The RSUs will vest on the earlier of June 30, 202", "url": "https://www.stocktitan.net/sec-filings/ADCT/form-4-adc-therapeutics-sa-insider-trading-activity-674e12b45bb0.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:17", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer", "summary": "ADC Therapeutics (ADCT) announced that its Chief Legal Officer, Peter J. Graham, was granted 221,100 restricted stock units (RSUs) on June 30, 2026, as part of an incentive award. These RSUs, which represent common shares, will vest on the earlier of June 30, 2027, or specific te", "url": "https://www.stocktitan.net/sec-filings/ADCT/form-4-adc-therapeutics-sa-insider-trading-activity-7ef6a267d0f6.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:17", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive retention awards approved at ADC Therapeutics (NYSE: ADCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQYjdNQldfbmZ6S3dJc0dWY25tdUlPbXkzRkc5TnRZeVVOcjBoTF80alBoNnNZSWlWNXNmbEp4MF9YOWk3TXJTQnpESmpteW14ODNCdzRuUDkySllVSmF4dFlBNXFtWjlxQzVFQmdvNVJtaHIwRXpMOGI4aGtIbDVsSGlVcmhEeHAtcjFaWTE5b2hCS0pheVU4X3Z3WnBhOE5jT1JlM0ZEZGJOZU5C?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Announces New Employee Inducement Grant", "summary": "ADC Therapeutics SA (NYSE: ADCT) has announced an inducement grant of options to purchase 17,000 common shares for a new employee. This grant, approved by the Compensation Committee, aims to retain top talent and relies on the employment inducement exemption under the NYSE's List", "url": "https://www.prnewswire.com/news-releases/adc-therapeutics-announces-new-employee-inducement-grant-302816307.html", "source_name": "PR Newswire", "published_at": "2026-07-01T20:05:19", "published_display": "01 Jul 2026 20:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics gives new hire 17,000-share inducement award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUUNhcFJ1WTZLdTNIUFVjWkFJeGVBYTJVajhvdjNNSzNBZkcwU3dqNUM1SnlCQ2xvZk5DTS1MUjRxVDQ0NHFiaG91TEFZOXNYZFNUeDI0T0JibFp3UHYzWE5hRUtvUl90U0JidUZLZ09JWllmWkhVUkxqSTFNWmdMQkZwWjlkMnV5ZndvOXhnR2N4Q2NwZDVKR3gxdmRGUEJTZlJXdDFtaTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL", "summary": "ADC Therapeutics has completed enrollment of 100 patients in its Phase 1b LOTIS-7 trial, evaluating a combination of ZYNLONTA and glofitamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial has shown an 89.8% overall response rate and a 77.6% complete resp", "url": "https://www.biopharminternational.com/view/adc-therapeutics-completes-enrollment-in-lotis-7-advancing-zynlonta-glofitamab-combination-in-dlbcl", "source_name": "BioPharm International", "published_at": "2026-06-30T18:10:27", "published_display": "30 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/adc-therapeutics-completes-enrollment-lotis-131624284.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:16:24+00:00", "published_display": "30 Jun 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics completes LOTIS-7 trial enrollment", "summary": "ADC Therapeutics has completed enrollment for its Phase 1b LOTIS-7 clinical trial, which investigates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 100 patients and aims to assess the saf", "url": "https://grafa.com/en/news/united-states/adc-therapeutics-lotis7-zynlonta-glofitamab", "source_name": "grafa.com", "published_at": "2026-06-30T14:10:27", "published_display": "30 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics completes enrollment in LOTIS-7 trial", "summary": "ADC Therapeutics has completed enrollment in its LOTIS-7 Phase 1b clinical trial, evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma. The company reported promising initial response rates from earlier data and anticipates s", "url": "https://www.investing.com/news/company-news/adc-therapeutics-completes-enrollment-in-lotis7-trial-93CH-4767528", "source_name": "Investing.com", "published_at": "2026-06-30T12:10:27", "published_display": "30 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial", "summary": "ADC Therapeutics announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA\u00ae in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients at the selected 150 \u00b5g/kg dose ", "url": "https://www.prnewswire.com/news-releases/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-302813948.html", "source_name": "PR Newswire", "published_at": "2026-06-30T11:10:27", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in ADC Therapeutics Ltd Stocks", "summary": "This article lists several ETFs that hold ADC Therapeutics Ltd (ADCT) stocks, providing financial details for each fund. The ETFs include those focused on small-cap growth, biotechnology, micro-cap companies, and healthcare innovation, with varying management styles and expense r", "url": "https://www.tradingview.com/symbols/NYSE-ADCT/etfs/", "source_name": "TradingView", "published_at": "2026-06-29T16:41:09", "published_display": "29 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index", "summary": "ADC Therapeutics SA (ADCT) has been added to the Russell Microcap Value Benchmark Index. This news follows a previous announcement on the same day that the company was added to the Russell 2000 Value Benchmark. The company, a clinical-stage oncology drug developer, recently repor", "url": "https://www.marketscreener.com/news/adc-therapeutics-sa-nyse-adct-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd988f724", "source_name": "marketscreener.com", "published_at": "2026-06-29T13:41:09", "published_display": "29 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma", "summary": "ADC Therapeutics (NYSE: ADCT) has completed enrollment for its LOTIS-7 Phase 1b trial, which evaluates ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study enrolled 100 patients across 30 sites, buil", "url": "https://www.stocktitan.net/news/ADCT/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-amg8g6sm2cgk.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:41:35", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of ADC Therapeutics SA \u2013 NYSE:ADCT", "summary": "This article provides financial information for ADC Therapeutics SA (NYSE: ADCT), specifically focusing on its enterprise value to revenue forward metric. The data is presented within the context of TradingView's platform, indicating that the metrics are available for investor an", "url": "https://www.tradingview.com/symbols/NYSE-ADCT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:40", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPN01uYUJZMzhXT0Nlckw1X01CdjVTcmVhaC12anpvdHhQWDExbTA0cm1zaDJkZXA3WHVTNEk1ZHpfekR1dW56c2w0d0ZicFFJMEZOcDU3UlF1ckwyVy10bmhXR3FsTFhtSjRqVjB4SXBydnU2bmVIM0RKZmhMcnU2cTdjd3R0SFpuNVBGcDR4UlZKQVlHODdzZQ?oc=5", "source_name": "Market source", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of ADC Therapeutics SA \u2013 NYSE:ADCT", "summary": "This article provides a brief financial data point for ADC Therapeutics SA (NYSE:ADCT), specifically regarding its price-to-earnings forward ratio. The content is sparse, indicating \"Period Value Change Change %\" but without specific numerical data. It appears to be a stub or a s", "url": "https://www.tradingview.com/symbols/NYSE-ADCT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:11:20", "published_display": "27 Jun 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Ltd Actuals & Estimates (NYSE:ADCT)", "summary": "This article provides an overview of ADC Therapeutics SA (NYSE:ADCT) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price targets, upcoming earnings dates, and past financial results lik", "url": "https://www.tradingview.com/symbols/NYSE-ADCT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:14", "published_display": "26 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics launches restructuring around ZYNLONTA", "summary": "ADC Therapeutics (NYSE:ADCT) is undergoing a strategic reorganization focusing on its ZYNLONTA franchise and related clinical trials. The restructuring involves an estimated 17% workforce reduction, expected to save $10 million annually, and aims to extend the company's cash runw", "url": "https://grafa.com/en/news/united-states/adc-therapeutics-restructuring-zylnonta-lotis", "source_name": "grafa.com", "published_at": "2026-06-24T16:11:03", "published_display": "24 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics plans 17% workforce cut to save ~$10M annually, $3M one-time charges", "summary": "ADC Therapeutics announced a global workforce reduction of approximately 17% to achieve about $10 million in annualized cost savings. This reduction is primarily due to the completion of the LOTIS-5 and LOTIS-7 programs and aims to enhance financial flexibility. The company expec", "url": "https://www.tradingview.com/news/tradingview:7482aefdde3ff:0-adc-therapeutics-plans-17-workforce-cut-to-save-10m-annually-3m-one-time-charges/", "source_name": "TradingView", "published_at": "2026-06-24T13:11:03", "published_display": "24 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (NYSE: ADCT) trims workforce 17% to back ZYNLONTA trials and extend cash runway", "summary": "ADC Therapeutics announced a strategic reorganization involving a 17% global workforce reduction to focus on its ZYNLONTA franchise. This move is expected to generate $10 million in annualized cost savings against $3 million in one-time charges, extending the company\u2019s cash runwa", "url": "https://www.stocktitan.net/sec-filings/ADCT/8-k-adc-therapeutics-sa-reports-material-event-0799bfe43e91.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:11:03", "published_display": "24 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Cuts 17% of Workforce, Targets $10 Million in Annual Savings", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/adc-therapeutics-cuts-17-workforce-114530049.html", "source_name": "MT Newswires", "published_at": "2026-06-24T11:45:30+00:00", "published_display": "24 Jun 2026 11:45", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA\u00ae Growth Opportunities and Regulatory Priorities", "summary": "ADC Therapeutics (NYSE: ADCT) has announced a strategic reorganization, including a 17% global workforce reduction, to enhance financial flexibility and focus on ZYNLONTA\u00ae growth. The company expects to save approximately $10 million annually, driven by the anticipated completion", "url": "https://www.prnewswire.com/news-releases/adc-therapeutics-announces-strategic-reorganization-to-support-zynlonta-growth-opportunities-and-regulatory-priorities-302808358.html", "source_name": "PR Newswire", "published_at": "2026-06-24T11:11:03", "published_display": "24 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics To Cut About 17% Of Its Staff \u2013 A Look At Some Key Details", "summary": "ADC Therapeutics (ADCT) announced a 17% workforce reduction to focus on its ZYNLONTA franchise and upcoming regulatory milestones, including a pre-supplemental Biologics License Application with the FDA in August 2026. This move is expected to generate $10 million in annualized c", "url": "https://stocktwits.com/news-articles/markets/equity/adc-therapeutics-in-focus-layoffs-reorganization-zynlonta-franchise/cZKya9bR7fg", "source_name": "Stocktwits", "published_at": "2026-06-24T09:13:00", "published_display": "24 Jun 2026 09:13", "sentiment": "negative", "sentiment_pct": 37, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics trims 17% of staff to fund ZYNLONTA push", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbXlGMkNsSkc2bk1HR3ZpU2laMHZVMEkxMVZqb1ViVEkyRTA0cEVIYWN1LUJXVUFNVUZSQmlZNmpJODM3SXdMcmpkSm9OczhaRFNCeU5vVnNqNGNGTXdYSkFibnVRRG9qQkJsemI1b3FqRGpYZkdGck1ZMHlYdW9hR3hVcE9xZnZaZjNBTExzOC1abnVXRUFjSzZVSU5mdWFMSGc0b2RSbmlpM1RKOEF4NmlILVZXN2Ez?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) following a significant drop in stock price. This investigation comes after ADC announced topline data from its Phase 3 LOTIS-5 trial, where their treatment,", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-adc-therapeu-1174146", "source_name": "ACCESS Newswire", "published_at": "2026-06-23T05:10:42", "published_display": "23 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (ADCT) following a significant drop in its stock price. This investigation comes after the announcement of top-line data from ADC's Phase 3 LOTIS-5 trial, which, despite extending pro", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1174144", "source_name": "ACCESS Newswire", "published_at": "2026-06-19T11:00:00", "published_display": "19 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ADC Therapeutics\u2019 loncastuximab tesirine is still on oncologists\u2019 radar", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOajVKZ2dGSGd1ajRaclNaNVZwQi02X0ZCV2s4QVRSSk9KS1lUbWZCYVk2UmpGdXJBU2x4VklLTXU2bTdzaF9pb2NkS3Y4YTcyRjM0RW5FTy0tNnk4LXU5T09ETWJub0JLWFpvZUh2eTkzQm01dHVuTEc3cnI0ZWpNWHowX0owVUUtRWZQdHRsTEpsYmc4TVVIdnJaLW1uLW5wandZUTlobzJqQ2RFaXFhMzlrcjMtVkpEOTEwTHBNcGgwdTRW?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-19T02:17:12+00:00", "published_display": "19 Jun 2026 02:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT", "summary": "Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (ADCT) on behalf of investors. This investigation follows a significant drop in ADC's stock price after the company released topline data from its Phase 3 LOTIS-5 trial for ZYNLONTA\u00ae, whi", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adc-therapeutics-sa---adct-302802881.html", "source_name": "PR Newswire", "published_at": "2026-06-18T13:59:46", "published_display": "18 Jun 2026 13:59", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics SA (ADCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for ADC Therapeutics SA (ADCT), detailing its business segments. It shows that Product sales account for 90.41% of revenue, followed by License revenue at 6.15%, and Royalties at 3.45%. The article also notes that relevant regional data f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-adct/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:46", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADC Therapeutics SA (NYSE:ADCT) following a significant stock price drop. This drop occurred after the company announced Phase 3 trial data for ZYNLONTA\u00ae, which, despite extending progression-free surviv", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/adc-therapeutics-sa-adct-investigation-bronstein-gewirtz-and-gro-1174142", "source_name": "ACCESS Newswire", "published_at": "2026-06-17T20:39:51", "published_display": "17 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) securities. This investigation follows the announcement of topline data from ADC's Phase 3 LOTIS-5 trial, where ZYNLONTA\u00ae extended progression-free survival ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-adc-therapeutics-s-1174140", "source_name": "ACCESS Newswire", "published_at": "2026-06-15T16:40:31", "published_display": "15 Jun 2026 16:40", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Shares Fall After HC Wainwright Downgrade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adc-therapeutics-shares-fall-hc-185243246.html", "source_name": "MT Newswires", "published_at": "2026-06-08T18:52:43+00:00", "published_display": "08 Jun 2026 18:52", "sentiment": "negative", "sentiment_pct": 22, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA Data - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQN0xDZGsxR1BWVkVQQ0xMUGF4OEJpQmRFcXB0SHNBN2UzaEpzTUhaN0hlRFh1WW5tZ01kQ2ctQVFTRGdqVjk3Z05BbHhCb1g1WlQzRWUwaHJuYVdmZGlfdVdhcXc3cUhkbE44R29EMmNweWxUdnAySUg3SWtkLXF4WVZnTGpFSjI4YW9Sa244eE9WUUt2TTJWZVg4eWlDS1k?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQS21uUlJGeEp6UmUzSlYwQ2pjYUswRk1XY2ljYU1jeUFTRzg5RDhzUzVUYlBQeHhIZ0ZIc3NwMFdnQ2RrcDA0blBxQUJYVXJUT0xOU2FYWkpqczhjd2FVZTJ5RmVPOUFQSi1fYzFMdGN4M1RGak01bjNGQ1BKNERCbXpXNHQ4ZHFEQ2xyOVktREU5U0pwWDBmb25NVERzUUZEN1JnUDJJTFVLak9iV1FtV1Z1VTYtdzE2LS03Tjdrd0hKRlFvSzlyc21vbGRDZXRUMDVtMU5tS0cwcjJFbXJSWGU1aEkzdw?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics plunges after patient deaths in blood cancer drug trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPQnNxUXE1czUwRnI5M2pHdklYQXZBQk5kUlJWZ2t5TEgtQ3A0Z2ZoRHFNejhNWi1MOElPVHdQOXcxYzl1akY3RS1DNE5HYTN4Q2oxMXB5SkFLWDFNQUltS3M2NGZKU0thLU1EMS01UnA0TTZWSl9QcU1zMkxPQXJKSG1lOTBFUEFyNVVCZEZqWWhYR2ZlalJtY2g5NEVNemxXNlBpdE1xeXREdjFUWTZtalRnSkUtNjMwNHJDRzZ6ZFY0TzlVR1A0V2RzUU9jaERLa2hEOUVpdzY?oc=5", "source_name": "Reuters", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LOTIS-5 trial: ADC Therapeutics (NYSE: ADCT) shows PFS gain but higher toxicity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQNGNraGE5OE1iNVJkV0pyRG1qYU9CUTBjS2daN1BXS2xsel9mSGFoWURoZzJqNVVraXF3a2VaZFdGeS1nSmNla2Q2ZU4yY1RGY0JsODAzd2xnOUVYSjBxdVFaUkFNdm1JQl9WREk5NWR3RUFBNHJLSmpKYkFsRklJbkd0aGp6YXhwNmRsbEFfczVBMHJfYWhicVJiSkNUaFdlNUpfNXEzVDRkbV9q?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics (ADCT) investors approve pay limits, equity plan and capital increases", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPajJhZW5TWWx5Tjd4azVEQ2RwSkx2N3Q3RDVQZkQ2eW1pcks0UmdxZGN6U09zNndDWjFxdHZhVXNtc3V0WWNKTFdCRHRDc2ZvZ0RHQjVqeExJaUktVjdFTWhyYnc0emV3d2g5aERhOUNSVkdSMWF5YkFMblZJOXJCTGdhOE5sNWZycVdCd2xHMlJVTVhVVl9LTGVnTkRUTUNRa20xd2VXd0hwbUY2?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNR045UFZhak5fQzVzQ3B2cnozeWFKN0luQnZCTC15dVlOcllyV1otSENPckVNd2ZlVnBac01JZUdwT0hfVVd2TERHNFk5OWEzbXNzNVZhZlE2TllMNk83ajRSWkh6d2pzS2pycVROVVd1ZjFfbllzVFZYeVBtczhCWll1Vi1wVGpfX0hwZDczYU9pc2ZlR25uWHEwaElaUVk1ZTRQamxpcGFpT0lrSS1vWXdIZmNjdXRkeXlkZ2dTODltMlBtem9DVktzbU5mU1lmeGVTR1dyV2MzVEJFejBHcXh5MHY?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNUkZjZVdlVEc4bUN1SFNrVGtIT0NWT1lqcDFlY0xnR2xPcnViUVBqMEJyYzJYUmJJRWp2SGV3SHNQemlOSkQ0VUI4dGFYd2VXQWdtR3R3VG9SNVhDbmp1VXRrb0kySUROMHk0TTZXY25JUDNJY2l3Q2h3XzFLakJvT1FuT00wSFdL0gGIAUFVX3lxTE1SRmNlV2VURzhtQ3VIU2tUa0hPQ1ZPWWpwMWVjTGdHbE9ydWJRUGowQnJjMlhSYklFanZIZXdIc1B6aU5KRDRVQjh0YVh3ZVdBZ21HdHdUb1I1WENuanVVdGtvSTJJRE4weTRNNldjbklQM0ljaXdDaHdfMUtqQm9PUW5PTTBIV0s?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new hires at ADC Therapeutics receive 49,400 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQQ3Y5cHNDYkRIYlRhM3RWQWR2cEZCV0p6WnAxazRQUExXcklOUmZfWnpRVFBzTlpFeTdEdGZGUk9zbmJvOW9ibmNQMlgzVVdqSG50TGFfalVvLTQwYWhTRzNCTkN0Q19kaHlmMDZnWjAtOEFQMzZvc1pIM093RnBSbHpCUzRoT3BqNXpkS2xKQ1VtT3JhTzlOaGZBcVUzUmJxQnlSVHVkVkxPSmFYQTAyUU95bHBBR3NxWmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcV9pVnVxQU53WGxVWXFMdndMczg2ZWgxSGgxcTNGcFM2c1dpUk5HMm0zMkMtU185dzBtWWRmUWoyOGRVUDF6SnV1WHJTOGhycUlMMnZDR2lhSXdpNm9EdEl3azg5SmhldXJHZEFqNGhodjAzLWp5Z3otQ0NKa2V0cjhZd05LdzROZXFzVGpXclQ1ZVhzWVBJNi1lcWtUR3gtS2gzWnZZLS0xdw?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbnFqeFdua2MzSW91bmQ5RHFCSDMyeDUxbllONlNCY2hLa040VVBzeER3WkRLRUtsNncwc081YVJPQ19VQUFCak0wVF9pWm41WmxaZFQ4STQ4a21xWXYzQjA0SzlmYS1xc3ZscTdCMjVQSVROSzRZaWtETm5NX1ZjeHowdGVsQkE1eG1YaWpiYU9WWFFpV2NPYlJRQ1NvZkhsY3BrQmR6ZzE4WGxEcG5DLXpsR3ZCVmhNTlRzUTF6OTJDXzFJY0p1YUxqVTVQQjRoUUtiU1Q1ZjlsZy1sckRPcG5tR0FhMnE3R3VZT3NoUEdJV2JFVDVZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQTUtxNENZNmN0eVl3QTJXZ19tWi15dC1xWVlHQmVBUVZuUEhnU21GalpoTG9vTW1HcjRBMGwtR2VEb3FXLU9tZlFLNWt4YThrcS04RzNoWjFYV000QmFDb0V0MzVGNVczT0J0UzVzbzh6VHJpX0RZdTlxRWx0ZEZHV05BRXI?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNUzdBRGhxRlYwRE5fczZCZDlsREJsQk1OYlpLY2VfMHBZdkNBSktqX3JBSzFEeTVTOEdaVW9kdzY5MHhkYTZVOGY3VkxvVWRfVVhKYnZOMHZoTzVvaHVwLUNha1JWWm5vMHhwSHhCZ2RVLXM2WXpsRkhfbEVELXlLWnpuZ2hKU1lKZnFrd1VMb01BSnJCX1JDN2wwY1Z3aVRJTGhDVG5xeS1PMFU4NkxIV2hFTndaeXRsQ2JNS252VFlPWmRpRWhYb0VHeVV0TjJvaUpma1BwRm1xSElxaDR2cHBMUFhCamVJ?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-12T07:00:00+00:00", "published_display": "12 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 57, "sentiment_summary": {"positive": 12, "negative": 12, "neutral": 33, "score": 49, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 1.29, "latest_week": "2026-07-10", "one_week_move": 8.4, "four_week_move": 22.9, "twelve_week_move": -69.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.288602, "market_dynamics_buy_signal": false, "relative_strength": -66.148159, "fair_value_gap": -53.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.6522, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.4% over one week, +22.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 9}, {"label": "PR Newswire", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "ACCESS Newswire", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "grafa.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 6}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+8.4% over one week, +22.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates"}], "updated_at": "2026-07-17T06:19:12.822894+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}